Abivax S.A.
ABVX.PA · PAR
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.17 | -0.07 | 0.08 | -0.04 |
| FCF Yield | -15.84% | -16.57% | -10.59% | -14.12% |
| EV / EBITDA | -4.90 | -4.13 | -8.74 | -3.30 |
| Quality | ||||
| ROIC | -166.92% | -65.27% | -31.93% | -33.70% |
| Gross Margin | 100.00% | 100.00% | 100.00% | 83.16% |
| Cash Conversion Ratio | 0.66 | 0.74 | 1.04 | 0.73 |
| Growth | ||||
| Revenue 3-Year CAGR | – | 1,197.35% | 249.81% | 123.07% |
| Free Cash Flow Growth | 5.74% | 17.17% | -22.63% | -140.20% |
| Safety | ||||
| Net Debt / EBITDA | -0.40 | 0.52 | 1.36 | 2.18 |
| Interest Coverage | -26.61 | -16.95 | -10.14 | -15.82 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 657.58 | -4,929.26 | 217.03 | -3,015.33 |